Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register  by Vajda, F.J.E. et al.
Seizure 19 (2010) 558–561Is lamotrigine a signiﬁcant human teratogen? Observations from
the Australian Pregnancy Register
F.J.E. Vajda a,*, J.E. Grahama, A.A. Hitchcock a, T.J. O’Brien a, C.M. Lander b, M.J. Eadie b
aDepartment of Medicine and Neurology, Royal Melbourne Hospital and University of Melbourne, Parkville, Victoria 3050, Australia
bRoyal Brisbane and Women’s Hospital and University of Queensland, Brisbane, Queensland 4027, Australia
A R T I C L E I N F O
Article history:
Received 27 May 2010
Accepted 30 July 2010
Keywords:
Antiepileptic drugs
Carbamazepine
Lamotrigine
Pregnancy
Teratogenicity
Valproate
A B S T R A C T
Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of
valproate (VPA), because of the teratogenic risks associated with the latter. It is therefore important to
know the teratogenic hazard associated with LTG, relative to VPA and to other commonly used
antiepileptic drugs (AEDs). Data from the Australian Register of Antiepileptic Drugs in Pregnancy was
examined to determine the incidence of teratogenicity determined 1 year from completion of pregnancy
in women who took AEDs in monotherapy during pregnancy. Compared with a 3.4% malformation
incidence in women who took no AEDs (N = 118), the incidences for LTG (N = 243), carbamazepine (CBZ)
(N = 302) and VPA (N = 224) were, respectively, 4.9%, 5.3% and 15.2%, the latter statistically signiﬁcantly
greater than the risk for no AED therapy in pregnant women with epilepsy. Logistic regression analysis
showed no tendency for foetal hazard to increase with increasing LTG dose in pregnancy, unlike the
situation for VPA. However, seizure control in pregnancy tended to be not as good in the women taking
LTG compared with those taking VPA, though the data examined were not adequate to permit deﬁnite
conclusions regarding this matter. We conclude that LTG monotherapy in pregnancy is safer than
valproate monotherapy from the point of view of foetal malformations, and no more hazardous in this
regard than therapy with other commonly used AEDs.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Although several antiepileptic drugs (AEDs) are more or less
equally effective in preventing the seizures of the partial epilepsies,
valproate (VPA) is widely accepted as the most effective therapy for
achieving seizure control in the primary generalised epilepsies. The
increasing evidence that valproate is an important human terato-
gen1–4 has therefore produced a considerable dilemma for the
management of women with primary generalised epilepsy who
wish to becomepregnant, or are already in early pregnancy. There is
now some evidence that, on a milligram (mg) for mg dosage basis,
VPA may be less teratogenic when combined with other AEDs.5 In
patients in whom it is decided to replace valproate with another
AED, whenever feasible before pregnancy commences, at the
present time lamotrigine (LTG) often seems to be the drug chosen.
However, this choice raises two questions, viz. (i) to what extent is
LTG itself a teratogen and (ii) how effective is LTG in controlling
maternal seizures during pregnancy. In the present paper data from* Corresponding author. Tel.: +61 398193056; fax: +61 398193056.
E-mail address: vajda@netspace.net.au (F.J.E. Vajda).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.07.019the Australian Pregnancy Register of Antiepileptic Drugs have been
examined with the aim of answering these questions.
2. Materials and methods
The Australian Pregnancy Register of Antiepileptic Drugs was
established in 1999 to collect information concerning pregnant
womenwith epilepsy,whether treatedwith AEDs or not, and also in
pregnantwomenwithdisordersother thanepilepsywhoare treated
with AEDs. Recruitment is nationwide and entirely voluntary,
potentially eligible women becoming aware of the Register by
various means, though most often by their treating medical
practitioners, nurses or allied health professionals, or by other
pregnant women. All contact with the Register is by telephone.
Relevant details are obtained frompregnantwomen on recruitment
(as far as possible in the ﬁrst or second trimester), at 7 months of
pregnancy, within the ﬁrst post-natal month and at the end of the
ﬁrst post-natal year and are entered into a database. Treating
medical practitioners are contacted to conﬁrm details. The foetal
malformation classiﬁcation used is that of the Birth Defects Registry
of Victoria.6 The Register database was housed initially at St.
Vincent’s Hospital, Melbourne, then at Monash University, Mel-
bourne, and is currently at the Royal Melbourne Hospital. Thevier Ltd. All rights reserved.
Table 1
Incidences of pregnancy with foetal malformation associated with exposure to monotherapy with each of the more commonly used AEDs. The malformation rates at 1 year
are calculated relative to the number of pregnancies present at the end of the ﬁrst post-natal month, not the ﬁrst post-natal year.
Drug N Malformation
(by 1 month)
% Malformation
(by 1 year)
% Odds ratio: by 1 year
data versus no AED
95% C.I.
No AED 118 4 3.4 4 3.4
CBZ 302 8 2.7 16 5.3 1.59 0.52, 4.97
LTG 243 7 2.9 12 4.9 1.48 0.47, 4.69
VPA 224 30 13.4 34 15.2 4.99 1.73, 14.44*
PHT 34 1 2.9 1 2.9
LEV 33 0 0 0 0
TPM 34 1 2.9 1 2.9
CZP 24 0 0 0 0
GPT 14 0 0 0 0
OxCBZ 8 0 0 0 0
PHT: phenytoin; LEV: levetriacetam; TPM: topiramate; CZP: clonazepam; GPT: gabapentin; OxCBZ: oxcarbazepine.
* P<0.05.
[(Fig._1)TD$FIG]
Fig. 1. Logistic regressions for the fraction of pregnancies associated with foetal
malformation relative to drug doses for LTG, CBZ, and VPA,with doses of these drugs
being expressed as multiples of their WHO deﬁned daily doses (DDDs).
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Research Ethics Committees of the above institutions.
All pregnancies in the Register that had gone to term live, or had
been terminated because of detected foetal abnormality, were
initially included in the analysis. Spontaneous abortions, stillbirths
and intrauterine deaths were excluded. Data relating to pregnan-
cies in whichmore than one AEDwas taken simultaneously during
the ﬁrst trimester of pregnancy were then excluded from further
consideration, because of the uncertainty in assigning roles in the
production of malformations and in achieving seizure control
when more than one active substance was involved.
All results were expressed in terms of pregnancies, not of
offspring, and a pregnancy involving one malformed twin was
regarded as a pregnancy with a malformation. The presence of
foetal malformations was determined on the basis of the
information available at the end of the ﬁrst post-natal month
and of the ﬁrst post-natal year, though some women included in
the analysis were lost to follow up by the end of the ﬁrst year, and
others had not reached that stage at the time of data analysis. The
presence or absence of seizure control in the pre-pregnancy year
and during pregnancy was noted at each times of interview, but a
more detailed study of seizure behaviour was not carried out
because not all women involved in the study keep daily seizure
diaries, and also had not kept them for their pre-pregnancy years.
The relationship between AED dosage and malformation risk
was assessed by means of logistic regression analysis. Statistical
signiﬁcances of differences were assessed using conﬁdence
interval analysis.
3. Results
3.1. Pregnancies with malformations—incidence
Therewere 1052 pregnancies exposed to AEDmonotherapy and
118 pregnancies in women who had not taken AEDs in at least the
ﬁrst trimester of their pregnancies. Table 1 sets out the risk of
malformation associated with monotherapy with the more
commonly prescribed AEDs, and with epilepsy unexposed to
any AED. The risks at the end of 1 year post-natally are likely to be
underestimates, because the rate has been expressed without
allowance for pregnancies untraceable by this stage and pregnan-
cies which had not reached the 12-month time-point. The risk of
malformation occurring in pregnancies exposed to VPA was
signiﬁcantly greater than the risk when any other AED had been
used in monotherapy in pregnancy. However the odds ratios for
the risks associated with exposure to the other commonly used
AEDs (CBZ and LTG) were also greater than 1.0, though not
signiﬁcantly so. The numbers associated with the other AEDs were
too small for useful analysis.3.2. Pregnancies with malformations—dose-related risk
If an AED is a teratogen, it might be anticipated that the risk of
foetal malformation in pregnancy would increase in relation to
increasing dosage exposure to that AED. Accordingly, logistic
regressions for the risk of pregnancy with malformation on AED
dose were calculated for the 3 AEDs commonly used in
monotherapy. The logistic regression equations were:
 LTG: logit risk = 2.698683  0.000962 dose; P intercept =
<.0001, P slope = .638
 CBZ: logit risk = 3.535977 + 0.001017 dose; P intercept =
<.0001, P slope = .1644
 VPA: logit risk = 3.031384 + 0.001193 dose; P intercept =
<.0001, P slope = .0001
The only statistically signiﬁcant regression was that for VPA,
though the regression for CBZ did show a tendency for the risk to
increase with increasing dosage. The risk for LTG tended to
diminish slightly as dose increased, but this did not approach
signiﬁcance. To enable the risks relative to dosage to be compared
visually, on a common dosage basis, Fig. 1 has been drawn to show
the logistic regressions for risk on dose for the 3 main AEDs after
drug dosage was converted to a multiple of theWHO deﬁned daily
doses for each drug (LTG 300 mg, CBZ 1000 mg, and VPA 1500 mg).
Table 2
Showing the rates of occurrence of seizures during pregnancy for LTG andVPAmonotherapy in those free from seizures, and those experiencing seizures, in the pre-pregnancy
year. Results are shown for all women with epilepsy and, separately, for those with primary generalised and with partial epilepsies.
Drug Seizures in year
before pregnancy
N= Seizures in
pregnancy
% Difference % 95% C.I. %
All epilepsy
LTG Free 134 36 26.9 10.8 1.4, 20.2*
VPA Free 162 26 16.0
LTG Present 116 93 80.1 20.8 6.75, 34.8*
VPA Present 64 38 59.4
Primary generalised
LTG Free 61 16 26.2 9.56 3.18, 22.3
VPA Free 132 22 16.7
LTG Present 42 28 66.7 3.88 16.4, 24.2
VPA Present 43 27 62.8
Partial
LTG Free 67 20 29.9 10.8 9.25, 30.9
VPA Free 21 4 19.0
LTG Present 69 60 87.0 22.3 1.82, 46.3
VPA Present 17 11 64.7
* P<0.05.
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In relation to seizure control, the clinical issue is whether LTG
monotherapy can achieve as good seizure control in pregnancy as
that produced by VPA, particularly in managing the primary
generalised epilepsies. Table 2 compares seizure control in the pre-
pregnancy year with control during pregnancy for LTG and VPA,
each used in monotherapy, in all women with epilepsy and,
separately, in those with diagnosed primary generalised and
partial epilepsies.
In all comparisons, seizure control relative to the pre-pregnancy
situation were better with VPA than with LTG, but the differences
were signiﬁcant only for all types of epilepsy taken together, and
not for the partial or the primary generalised epilepsy sub-
populations alone. Interestingly, 71.7% of those on VPA had at least
1 year’s seizure control before pregnancy began, compared with
53.6% for LTG. Not unexpectedly, thosewomenwith seizures in the
pre-pregnancy year were more likely to continue to experience
seizures during pregnancy. The overall 36% incidence of uncon-
trolled epilepsy in the pre-pregnancy year raises unanswerable
questions regarding the adequacy of treatment provided, and of
patient compliance.
4. Discussion
The present analysis has shown no statistically signiﬁcant
difference between the risk of foetal malformation and exposure to
LTG monotherapy in pregnancy, and that which applied when
pregnant women with epilepsy took no AEDs. This ﬁnding is
consistent with the ﬁndings of other studies which have also
shown no enhanced hazard formalformations in relation to the use
of LTG in pregnancy3,7 though Morrow et al.3 did ﬁnd a higher
mean LTG dose taken in pregnancies associated with foetal
malformation. The present study, employing logistic regression
analysis, has shown no evidence of an increased malformation risk
as LTG dose in pregnancy increases. It therefore seems that, at least
from the foetal point of view, LTG monotherapy in pregnancy is
probably distinctly safer than VPA monotherapy, and no less safe
than CBZ monotherapy.
Unfortunately, the present study does not deﬁnitely answer the
question of whether LTG monotherapy is as satisfactory as VPA
monotherapy in controlling seizures during pregnancy. The data of
Table 2 suggest that it is not, in keeping with the conclusion of
Mazurkiewicz-Bledzinska et al.8. However, the data available to
the present study have rather substantial limitations. No
standardised seizure diaries were kept by the women studied,either before or during pregnancy. Therefore information con-
cerning the occurrence of seizures was retrospectively acquired
and highly dependent on the accuracy of thewomen’s recall. Given
that 36% of the women in their pre-pregnancy year had seizures
that were not controlled by AED monotherapy, and yet did not
receive AED polytherapy, one must wonder how adequate had
been theirmanagement. Onemight alsowonderwhether the same
inadequacy ofmanagementmay have continued in pregnancy and,
in particular, whether the considerably increased clearance of LTG
in this situation9,10 had been taken into account in determining
drug dosages. There the allocation of drugs to the pregnant women
was not random, and therewas nomatching of the patients or their
epilepsies. Consequently it may be unwise to draw ﬁrm conclu-
sions about comparative drug efﬁcacy from the seizure data from
this analysis in the present study. Nonetheless, the impression
remains that women who want to avoid the foetal hazards of VPA
monotherapy by taking LTGmay trade an increased risk of seizures
during pregnancy, with the social and psychological consequences
that may entail, for a greater margin of safety for their babies.
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